Last reviewed · How we verify

NCT03718780: TEASE

Assessment of Continuous Measurement of Transcutaneous CO2 for Evaluation of Alveolar Dead Space During Exercise

Status unknown NA Last updated 14 June 2022
What this trial tests

NA trial testing simultaneous determination of PaCO2 and PtCO2 in Pulmonary Disease, Chronic Obstructive in 105 participants. Status unknown.

Timeline
22 February 2019
Primary endpoint
22 February 2024
22 February 2024

Quick facts

Lead sponsorCentre Hospitalier Metropole Savoie
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposeother
Enrollment105
Start date22 February 2019
Primary completion22 February 2024
Estimated completion22 February 2024
Sites4 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre Hospitalier Metropole Savoie

Who can join

18 and older, any sex, with Pulmonary Disease, Chronic Obstructive or Lung Diseases, Interstitial. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aim is to monitor, during exercise tests carried out in various conditions, the alveolar dead space, by means of continuous transcutaneous measurement of Pt CO2, which would be used as a surrogate for arterial PaCO2. Validity of this measurement needs to be assessed against arterial sampling (either arterial, or arterialized capillary), especially with regards to the lag time required by the CO2 diffusion from the arterial compartment (PaCO2) to the cutaneous one (PtCO2), in particular when rapid changes of CO2 might be induced by exercise. The evaluation will be done in 2 different settings: * intensive care patients, equipped, for their routine clinical care, with an arterial line; this allows for a precise timed comparison between PaCO2 and PtCO2 readouts; * routine exercise test, where blood gas evaluation is done essentially by means of arterialized earlobe capillary sampling. Following assessment of validity of the measurement (and the lag time PaCO2-PtCO2 which might be necessary to introduce as a correction), evolution of dead space during excise test will be tested in different conditions: Healthy subjects, patients with Chronic Obstructive Pulmonary Disease (COPD), chronic heart failure (CHF), hyperventilation, Pulmonary artery hypertension (PAH), or interstitial lung disease (ILD)

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Pulmonary Disease, Chronic Obstructive

Currently open trials in the same condition.

Other Centre Hospitalier Metropole Savoie trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03718780.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing